STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals

STAT PlusPharmalot Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals The drug maker stopped offering discounts last month to reduce what it calls duplicate discounts paid to the hospitals Manage alerts for this article Email this article Share this article By Ed SilvermanJuly 2, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Dozens of Congressional lawmakers are urging the Trump administration to force Eli Lilly to reinstate mandated price breaks to hospitals that participate in a federal drug discount program but have refused to provide the company with claims data. In a letter to U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr., the bipartisan group of lawmakers argued that Lilly is failing to comply with federal law by eliminating the price breaks. The drugmaker stopped offering discounts last month to reduce what it calls duplicate discounts paid to the hospitals.Advertisement At the time, Lilly targeted 50 larger hospital systems among approximately 1,000 hospitals that had not complied with a new policy that was announced earlier this year. The company maintained that roughly 70% of the hospitals that participate in the discount program, or more than 2,300, had previously provided claims data. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In drug pricing, hospitals, Pharmaceuticals, Policy, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Pharmalot July 2, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Pharmalot July 2, 2026 STAT Plus: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more Advertisement Pharmalot July 2, 2026 STAT Plus: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug Pharmalot July 1, 2026 STAT Plus: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more Pharmalot June 30, 2026 STAT Plus: Pharmalittle: We’re reading about Chinese trial sites being probed, RFK Jr. and peptides, and more Subscriber Picks